 |
29 Products |  |
56 Diseases | | 29 Products |
|
154 Trials |  |
7480 News |  |
| «12...87888990919293949596979899» |
- | Cimzia (certolizumab pegol) / Astellas, UCB
New P1 trial: CRIB: A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta (clinicaltrials.gov) - Dec 22, 2013
P1, N=20, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
- ||| Zomacton (somatropin) / Ferring
Adherence: ZOMAXEPT: Evaluation of the Adherence and the Patient Acceptability of Zomacton (clinicaltrials.gov) - Dec 19, 2013
P=N/A, N=90, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- |||||||||| Firmagon (degarelix) / Astellas, Ferring
New P3 trial: An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer (clinicaltrials.gov) - Dec 17, 2013
P3, N=220, Enrolling by invitation, Sponsor: Ferring Pharmaceuticals
- |||||| Firmagon (degarelix) / Astellas, Ferring
Enrollment open: An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer (clinicaltrials.gov) - Dec 12, 2013
P3, N=220, Enrolling by invitation, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Enrolling by invitation
- Firmagon (degarelix) / Astellas, Ferring
New P2 trial: TRial on the Endocrine Activity of Neoadjuvant Degarelix (clinicaltrials.gov) - Dec 5, 2013
P2, N=50, Not yet recruiting, Sponsor: International Breast Cancer Study Group
- ||||| Firmagon (degarelix) / Astellas, Ferring
New P2 trial: GETUG-AFU22: Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy (clinicaltrials.gov) - Nov 21, 2013
P2, N=120, Recruiting, Sponsor: UNICANCER
- Xtandi (enzalutamide capsule) / Pfizer, Astellas, Mekinist (trametinib) / Novartis, BeiGene, Firmagon (degarelix) / Astellas, Ferring
New P2 trial: Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer (clinicaltrials.gov) - Nov 19, 2013
P2, N=45, Not yet recruiting, Sponsor: University of California, Los Angeles
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s) (clinicaltrials.gov) - Nov 13, 2013
P=N/A, N=125, Recruiting, Sponsor: Pope Research Corporation
Not yet recruiting --> Enrolling by invitation N=300 --> 125
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate (clinicaltrials.gov) - Nov 12, 2013
P4, N=892, Active, not recruiting, Sponsor: UCB Pharma SA
N=300 --> 125 Recruiting --> Active, not recruiting
- ||| Lutrelef (gonadorelin acetate) / Ferring
New P3 trial: LutrePulse Hypogonadotropic Hypogonadism (clinicaltrials.gov) - Nov 4, 2013
P3, N=36, Recruiting, Sponsor: Ferring Pharmaceuticals
- ||||| Testavan (transdermal testosterone gel 2%) / Ferring
Enrollment change: A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel (clinicaltrials.gov) - Oct 30, 2013
P3, N=145, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting N=200 --> 145
- ||||||| Testavan (transdermal testosterone gel 2%) / Ferring
Trial completion: A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel (clinicaltrials.gov) - Oct 30, 2013
P3, N=145, Completed, Sponsor: Ferring Pharmaceuticals
N=200 --> 145 Enrolling by invitation --> Completed
- |||||| Bravelle (urofollitropin) / Ferring
Enrollment open, Head-to-Head: Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program (clinicaltrials.gov) - Oct 27, 2013
P3, N=200, Recruiting, Sponsor: Ferring Pharmaceuticals
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting
- |||||| Bravelle (urofollitropin) / Ferring
Enrollment open, Head-to-Head: Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females (clinicaltrials.gov) - Oct 22, 2013
P3, N=180, Recruiting, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Pentasa (mesalamine) / Ferring, Takeda
Enrollment change: Tolerability of Pentasa Sachet in Patients With Ulcerative Colitis (clinicaltrials.gov) - Oct 17, 2013
P=N/A, N=568, Completed, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting N=900 --> 568
- |||||| Rekovelle (follitropin delta) / Ferring
Enrollment open: ESTHER-2: Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2 (clinicaltrials.gov) - Oct 17, 2013
P3, N=400, Enrolling by invitation, Sponsor: Ferring Pharmaceuticals
N=900 --> 568 Not yet recruiting --> Enrolling by invitation
- ||| Pentasa (mesalamine) / Ferring, Takeda
Trial completion: Tolerability of Pentasa Sachet in Patients With Ulcerative Colitis (clinicaltrials.gov) - Oct 17, 2013
P=N/A, N=568, Completed, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed
- |||||| Rekovelle (follitropin delta) / Ferring
Enrollment open: ESTHER-1: Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1 (clinicaltrials.gov) - Oct 16, 2013
P3, N=1150, Recruiting, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Firmagon (degarelix) / Astellas, Ferring
New P3 trial: A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer (clinicaltrials.gov) - Oct 15, 2013
P3, N=230, Recruiting, Sponsor: Astellas Pharma Inc
- |||||| Firmagon (degarelix) / Astellas, Ferring
Enrollment open: A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer (clinicaltrials.gov) - Oct 14, 2013
P3, N=230, Recruiting, Sponsor: Astellas Pharma Inc
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Rekovelle (follitropin delta) / Ferring
New P3 trial: ESTHER-2: Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2 (clinicaltrials.gov) - Oct 6, 2013
P3, N=400, Enrolling by invitation, Sponsor: Ferring Pharmaceuticals
- |||||||||| Rekovelle (follitropin delta) / Ferring
New P3 trial: ESTHER-1: Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1 (clinicaltrials.gov) - Oct 6, 2013
P3, N=1150, Recruiting, Sponsor: Ferring Pharmaceuticals
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change, HEOR: RA-PROACTIVE: Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia (clinicaltrials.gov) - Sep 25, 2013
P=N/A, N=145, Active, not recruiting, Sponsor: UCB, Inc.
Not yet recruiting --> Recruiting N=187 --> 145
- |||||| Goofice (elobixibat) / Eisai, Mochida, Ipsen
Enrollment open: Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Sep 23, 2013
P3, N=900, Enrolling by invitation, Sponsor: Ferring Pharmaceuticals
N=187 --> 145 Not yet recruiting --> Enrolling by invitation
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial initiation date: NIMRA: Novel Imaging Markers for Rheumatoid Arthritis (clinicaltrials.gov) - Sep 22, 2013
P4, N=20, Active, not recruiting, Sponsor: University of California, San Francisco
Not yet recruiting --> Enrolling by invitation Initiation date: Feb 2013 --> Oct 2013
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial termination: NURTURE: The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents (clinicaltrials.gov) - Sep 17, 2013
P2, N=99, Terminated, Sponsor: UCB Celltech
Initiation date: Feb 2013 --> Oct 2013 Completed --> Terminated; higher than projected discontinuation rate during Maintenance Phase
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Sep 15, 2013
P=N/A, N=1360, Recruiting, Sponsor: UCB Pharma SA
Completed --> Terminated; higher than projected discontinuation rate during Maintenance Phase N=1814 --> 1360
- |||||||||| Hernicore (condoliase) / Seikagaku, Ferring
New P3 trial: A Study of SI-6603 in Patients With Lumbar Disc Herniation (clinicaltrials.gov) - Sep 11, 2013
P3, N=360, Recruiting, Sponsor: Seikagaku Corporation
- |||||| Hernicore (condoliase) / Seikagaku, Ferring
Enrollment open: A Study of SI-6603 in Patients With Lumbar Disc Herniation (clinicaltrials.gov) - Sep 11, 2013
P3, N=360, Recruiting, Sponsor: Seikagaku Corporation
N=1814 --> 1360 Not yet recruiting --> Recruiting
- | Yervoy (ipilimumab) / BMS
Enrollment closed: Ipilimumab + Androgen Depravation Therapy in Prostate Cancer (clinicaltrials.gov) - Sep 9, 2013
P2, N=48, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Hernicore (condoliase) / Seikagaku, Ferring
Trial completion: Clinical Trial to Assess Safety of SI-6603 in Patients With Lumbar Disc Herniation (clinicaltrials.gov) - Sep 4, 2013
P2, N=18, Completed, Sponsor: Seikagaku Corporation
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
Enrollment change: A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816) (clinicaltrials.gov) - Aug 15, 2013
P1, N=17, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=30 --> 17
- | Rebyota (fecal microbiota, live-jslm) / Ferring
New P2 trial: Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea (clinicaltrials.gov) - Aug 15, 2013
P2, N=40, Active, not recruiting, Sponsor: Rebiotix Inc.
- |||||||||| Bravelle (urofollitropin) / Ferring
New P3 trial, Head-to-Head: Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females (clinicaltrials.gov) - Aug 13, 2013
P3, N=180, Recruiting, Sponsor: Ferring Pharmaceuticals
- |||||||||| Bravelle (urofollitropin) / Ferring
New P3 trial, Head-to-Head: Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program (clinicaltrials.gov) - Aug 12, 2013
P3, N=200, Recruiting, Sponsor: Ferring Pharmaceuticals
- | Menopur (menotropin) / Ferring, Follistim AQ Cartridge (follitropin beta) / Organon, Bravelle (urofollitropin) / Ferring
New P4 trial: Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study (clinicaltrials.gov) - Aug 11, 2013
P4, N=100, Completed, Sponsor: Carolinas Healthcare System
- | Cervidil (dinoprostone) / Ferring
New P2 trial: Safety and Efficacy of Dinoprostone (Propess) in the Women With Premature Rupture of Membrane or Gestational Age <38 (clinicaltrials.gov) - Aug 1, 2013
P2, N=194, Recruiting, Sponsor: Seoul National University Hospital
- |||| Euflexxa (hyaluronic acid) / Ferring
Enrollment open: Effectiveness Trial for Evaluating IAHA for PFPS (clinicaltrials.gov) - Aug 1, 2013
P4, N=68, Recruiting, Sponsor: New York University School of Medicine
N=30 --> 17 Not yet recruiting --> Recruiting
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na (clinicaltrials.gov) - Jul 28, 2013
P3, N=880, Active, not recruiting, Sponsor: UCB, Inc.
Not yet recruiting --> Recruiting N=600 --> 880
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na (clinicaltrials.gov) - Jul 28, 2013
P3, N=880, Active, not recruiting, Sponsor: UCB, Inc.
N=600 --> 880 Recruiting --> Active, not recruiting
- | Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: PreCePRA: Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain (clinicaltrials.gov) - Jul 24, 2013
P3, N=156, Recruiting, Sponsor: University of Erlangen-N
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Firmagon (degarelix) / Astellas, Ferring
Enrollment change, PARP Biomarker: Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer (clinicaltrials.gov) - Jul 23, 2013
P=N/A, N=45, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting N=30 --> 45
- ||||||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer (clinicaltrials.gov) - Jul 22, 2013
P3, N=220, Completed, Sponsor: Ferring Pharmaceuticals
N=30 --> 45 Active, not recruiting --> Completed
- Firmagon (degarelix) / Astellas, Ferring
Trial termination: A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer (clinicaltrials.gov) - Jul 21, 2013
P2, N=5, Terminated, Sponsor: Ottawa Hospital Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Negative study; Principal Investigator chose to prematurely terminate the study.
- Firmagon (degarelix) / Astellas, Ferring
Enrollment change: A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer (clinicaltrials.gov) - Jul 21, 2013
P2, N=5, Terminated, Sponsor: Ottawa Hospital Research Institute
Active, not recruiting --> Terminated; Negative study; Principal Investigator chose to prematurely terminate the study. N=40 --> 5
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na (clinicaltrials.gov) - Jul 14, 2013
P3, N=880, Active, not recruiting, Sponsor: UCB Pharma SA
N=40 --> 5 Recruiting --> Active, not recruiting
- | Euflexxa (hyaluronic acid) / Ferring
New P4 trial, MRI: To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection (clinicaltrials.gov) - Jul 9, 2013
P4, N=12, Recruiting, Sponsor: University of California, San Francisco
- |||||||||| Goofice (elobixibat) / Eisai, Mochida, Ipsen
New P3 trial: Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Jul 8, 2013
P3, N=900, Enrolling by invitation, Sponsor: Ferring Pharmaceuticals
- Euflexxa (hyaluronic acid) / Ferring
Trial completion: Prediction of Response to Intra-articular Injections of Hyaluronic Acid for Knee Osteoarthritis (clinicaltrials.gov) - Jul 8, 2013
P4, N=207, Completed, Sponsor: American Orthopaedic Society for Sports Medicine
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: Study to Find Maintenance Dose for Periodic Administration of ASP3550 (clinicaltrials.gov) - Jul 7, 2013
P2, N=155, Completed, Sponsor: Astellas Pharma Inc
Recruiting --> Completed Active, not recruiting --> Completed